Literature DB >> 30787047

Benefits of Enhancing Nicotinamide Adenine Dinucleotide Levels in Damaged or Diseased Nerve Cells.

Andrew A Pieper1,2,3, Steven L McKnight4.   

Abstract

Three unbiased lines of research have commonly pointed to the benefits of enhanced levels of nicotinamide adenine dinucleotide (NAD+) to diseased or damaged neurons. Mice carrying a triplication of the gene encoding the culminating enzyme in NAD+ salvage from nicotinamide, NMNAT, are protected from a variety of insults to axons. Protection from Wallerian degeneration of axons is also observed in flies and mice bearing inactivating mutations in the SARM1 gene. Functional studies of the SARM1 gene product have revealed the presence of an enzymatic activity directed toward the hydrolysis of NAD+ Finally, an unbiased drug screen performed in living mice led to the discovery of a neuroprotective chemical designated P7C3. Biochemical studies of the P7C3 chemical show that it can enhance recovery of NAD+ from nicotinamide by activating NAMPT, the first enzyme in the salvage pathway. In combination, these three unrelated research endeavors offer evidence of the benefits of enhanced NAD+ levels to damaged neurons.
© 2018 Pieper and McKnight; Published by Cold Spring Harbor Laboratory Press.

Entities:  

Year:  2019        PMID: 30787047     DOI: 10.1101/sqb.2018.83.037622

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  6 in total

1.  Maternal treatment with P7C3-A20 protects from impaired maternal care after chronic gestational stress.

Authors:  Rachel Schroeder; Lynn Nguyen; Andrew A Pieper; Hanna E Stevens
Journal:  Behav Brain Res       Date:  2021-08-25       Impact factor: 3.332

2.  Reducing acetylated tau is neuroprotective in brain injury.

Authors:  Min-Kyoo Shin; Edwin Vázquez-Rosa; Yeojung Koh; Matasha Dhar; Kalyani Chaubey; Coral J Cintrón-Pérez; Sarah Barker; Emiko Miller; Kathryn Franke; Maria F Noterman; Divya Seth; Rachael S Allen; Cara T Motz; Sriganesh Ramachandra Rao; Lara A Skelton; Machelle T Pardue; Steven J Fliesler; Chao Wang; Tara E Tracy; Li Gan; Daniel J Liebl; Jude P J Savarraj; Glenda L Torres; Hilda Ahnstedt; Louise D McCullough; Ryan S Kitagawa; H Alex Choi; Pengyue Zhang; Yuan Hou; Chien-Wei Chiang; Lang Li; Francisco Ortiz; Jessica A Kilgore; Noelle S Williams; Victoria C Whitehair; Tamar Gefen; Margaret E Flanagan; Jonathan S Stamler; Mukesh K Jain; Allison Kraus; Feixiong Cheng; James D Reynolds; Andrew A Pieper
Journal:  Cell       Date:  2021-04-13       Impact factor: 41.582

3.  Maternal P7C3-A20 Treatment Protects Offspring from Neuropsychiatric Sequelae of Prenatal Stress.

Authors:  Rachel Schroeder; Preethy Sridharan; Lynn Nguyen; Alexandra Loren; Noelle S Williams; Kavitha P Kettimuthu; Coral J Cintrón-Pérez; Edwin Vázquez-Rosa; Andrew A Pieper; Hanna E Stevens
Journal:  Antioxid Redox Signal       Date:  2021-01-29       Impact factor: 7.468

Review 4.  NAD+ Metabolism and Diseases with Motor Dysfunction.

Authors:  Samuel Lundt; Shinghua Ding
Journal:  Genes (Basel)       Date:  2021-11-09       Impact factor: 4.096

5.  P7C3-A20 treatment one year after TBI in mice repairs the blood-brain barrier, arrests chronic neurodegeneration, and restores cognition.

Authors:  Edwin Vázquez-Rosa; Min-Kyoo Shin; Matasha Dhar; Kalyani Chaubey; Coral J Cintrón-Pérez; Xinmiao Tang; Xudong Liao; Emiko Miller; Yeojung Koh; Sarah Barker; Kathryn Franke; Danyel R Crosby; Rachel Schroeder; Josie Emery; Terry C Yin; Hisashi Fujioka; James D Reynolds; Matthew M Harper; Mukesh K Jain; Andrew A Pieper
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-21       Impact factor: 11.205

6.  Nampt activator P7C3 ameliorates diabetes and improves skeletal muscle function modulating cell metabolism and lipid mediators.

Authors:  Ravikumar Manickam; Jared Tur; Sachin L Badole; Kalyan C Chapalamadugu; Puja Sinha; Zhiying Wang; David W Russ; Marco Brotto; Srinivas M Tipparaju
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-01-21       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.